



US006410339B1

(12) **United States Patent**
Märin

(10) **Patent No.:** **US 6,410,339 B1**
(45) **Date of Patent:** ***Jun. 25, 2002**

(54) **PREPARATION FOR DIAGNOSIS OF THE METABOLIC SYNDROME AND DISEASES INCLUDING THE SYNDROME**

(75) Inventor: **Per Märin**, Göteborg (SE)

(73) Assignee: **Cortenda AB**, Gothenburg (SE)

(*) Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **08/952,638**

(22) PCT Filed: **May 30, 1996**

(86) PCT No.: **PCT/SE96/00708**

§ 371 (c)(1),

(2), (4) Date: **Feb. 26, 1998**

(87) PCT Pub. No.: **WO96/38179**

PCT Pub. Date: **Dec. 5, 1996**

(30) **Foreign Application Priority Data**

May 30, 1995 (SE) 9501991

(51) **Int. Cl.⁷** **G01N 33/53**; C12Q 3/00

(52) **U.S. Cl.** **436/500**; 436/501; 436/516;
435/3; 435/4

(58) **Field of Search** 436/500, 501,
436/516; 435/4, 3

(56) **References Cited**

PUBLICATIONS

Atkinson, et al. : A weight-related intravenous dexamethasone . . . : Acta Endocrin.: 120, 6: pp. 753–759, 1989.*
Croughs, et al. : Comparison of oral and intravenous dexamethasone . . . : Acta Endocrin.: 72: pp. 51–62, 1973.*

Montwill, et al. : The overweight dexamethasone test is the procedure . . . : Steroids: 59: pp. 296–298, May 1994.*

Bennington, et al: Saunders dictionary & encyclopedia of laboratory medicine and technology: p. 398, Jan. 1987.*

Hormone and metabolic research, vol. 22, 1990 pp. 553–554
Hagg, et al; Salivary Control during an . . .

Neuropsychobiology, vol. 22, 1989: pp. 26–32 Maes et al;
Results of the 8 a.m. dexamethasone . . .

DN Brindley, Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome, International Journal of Obesity (1995) 19, Suppl. 1 S69–S75.

Niklas Darin, Telko Amemiya, Bjorn Anderson, Sverker Jern and Per Bjorntorp, Cortisol Secretion in Relationship to Body Fat Distribution in Obese Premenopausal Women, Metabolism, vol. 41, No. 8 (Aug.) 1992 pp. 882–888.

(List continued on next page.)

Primary Examiner—Hankyel T. Park

Assistant Examiner—S. S. Brown

(74) *Attorney, Agent, or Firm*—Bradley N. Ruben

(57)

ABSTRACT

The use of cortisol agonist for preparing a system for diagnosis of the Metabolic Syndrome and related conditions as belly fatness, insulin resistance including increased risk of developing senile diabetes, i.e., diabetes type II, high blood fats and high blood pressure, in which system the dose of cortisol agonist is in an interval where a difference is obtained in the inhibitory effect of the autoproduct of cortisol in individuals suffering from the Metabolic Syndrome, compared to normal values.

13 Claims, 1 Drawing Sheet

